A hundred years of replacing pancreatic therapy; the history of Pankreon development

1. Kuhlmann Н. In: Rudmann M.A., ed. The magic potions in the belly gland. Hannover: Solvay Pharmaceuticals GmbH; 2000.

2. Rapaille M. Solvay. Ein Mann und sein Werk. Brussels: Didier Hatier; 1991.

3. Gockel M. Uber Erfolge mit ’Pankreon’, einem neuen, gegen Magensaft widerstandsfähigen Pankreaspraparat. Cbl. Stoffwechsel- и. Verdauungskrankheit. 1900; 11: 251—256.

4. Von Noorden C. Zur Diagnostik der Pankreaserkrankungen. Klin.-ther. Wschr. 1908; 35: 929—934.

5. Peschke G. Solvay Pharmaceuticals GmbH (data on file), 2000.

6. Smyth R.L. et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995; 346: 1247—1251.

7. Prescott P., Bakowski M.T. Pathogenesis of fibrosing colonopathy: the role of methacrylic acid copolymer. Pharmacoepidemiol. Drug Saf. 1999; 8: 377—384.

8. Bansi D.S. et al. Fibrosing colonopathy in an adult owing to overuse of pancreatic enzyme supplements. Gut 2000; 46: 283—285.

9. Littlewood J.M., Wolfe S.P. Control of malabsorption in cystic fibrosis. Paediatr. Drugs 2000; 3: 205—222.

10. Apte M.V. et al. Chronic pancreatitis: complications and management. J. Clin. Gastroenterol. 1999; 29: 225—240.

11. Mohan V. et al. Oral pancreatic enzyme therapy in the control of diabetes mellitus in tropical calculous pancreatitis. Int. J. Pancreatol. 1998; 24: 19—22.

12. Van Hoozen C.M. et al. Efficacy of enzyme supplementation after surgery for chronic pancreatitis. Pancreas 1997; 14: 174—180.

13. Neoptolemos J.P. et al. T rea tm en t of pancreatic exocrine insufficiency after pancreatic resection. Int. J. Pancreatol. 1999; 25: 171—180.

14. Bragelmann R. et al. The effect of pancreatic enzyme supplementation in patients with steatorhoea after gastrectomy. Eur. J. Gastroenterol. Hepatol. 1999; 11: 231—237.

15. Kitagawa M. et al. Evaluating exocrine function te s ts for diagnosing chronic pancreatitis. Pancreas 1997; 15: 402—408.

16. Rathmann W. et al. Pancreatic exocrine insufficiency and type 2 diabetes are strongly associated. Diabetologia 1999; 42 (suppl.lA): 297.

17. George D.E. et al. Comparison of two pancreatic enzyme supplements in pa tien ts with cystic fibrosis. Adv. Ther. 1990; 7: 109—118.

18. Friesen C., Prestidge С. Comparison of a high-strength pancreatic enzyme preparation and a standard-strength preparation in cystic fibrosis. Ibid. 1995; 12: 236—244.

19. Braden B. et al. Monitoring pancreatin supplementation in cystic fibrosis patients with the 13C-Hiolein® breath test: evidence of normalized fat assimilation with high dose pancreatin therapy. Z. Gastroenterol. 1997; 35: 123—129.

20. Lankisch P.G. Conservative trea tm en t of chronic pancreatitis. Digestion 1987; 37 (supp l.l): 47—55.

21. Vyas H. et al. A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis: A controlled study. Eur. J. Pediatr. 1990; 149: 241—243.

22. Layer P., Holtmann G. Pancreatic enzymes in chronic pancreatitis. Int. J. Pancreatol. 1994; 15: 1—11.

23. Meyer J.H. et al. Human postprandial g astric emptying of 1—3 millimeter spheres. Gastroenterology 1988; 94: 1315—1325.

24. Kuhnelt P., Mundlos S., Adler G. Einfluss der Pelletgosse eines Pankreasenzympraparates auf die duodenale lipolytische Aktivität. Z. Gastroenterol. 1991; 29: 417—421.

25. Mundlos S., Kuhnelt P., Adler G. Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test. Gut 1991; 31: 1324—1328.

26. Layer P. et al. Enzyme pellet size and luminal n u trient digestion in pancreatic insufficiency. Digestion 1992; 52: 100.

27. Norregard P. et al. Gastric emptying of pancreatin granules and dietary lipids in pancreatic insufficiency. Aliment. Pharmacol. Ther. 1996; 10: 427—432.

28. Lippold B.C. What is the ideal size for enteric-coated pancreatic preparations? Drugs made in Germany 1998; 41: 52—56.

29. Beverley D.W. et al. Comparison of four different pancreatic extracts in cystic fibrosis. Arch. Dis. Child. 1987; 62: 564—568.

30. Stead R.J. et al. Treatment of ste ato rrh o ea in cystic fibrosis: A comparison of enteric coated microspheres of pancreatin versus non-enteric coated pancreatin and adjuvant cimetidine. Aliment. Pharmacol. Ther. 1988; 2: 471—482.

31. Whitehead A.M. Stu d y to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations. Pharm. Weekbl. (Sei.) 1988; 10: 12—16.

32. Atkinson S.N. A comparative study of enzyme activity, acid resistance and dissolution characteris tics of four enteric coated microsphere preparations of pancreatin. Eur. J. Clin. Res. 1991; 1: 37—45.

33. Huwel S., Behrens R., Spener F. Pankreasenzyme: Präparate im Vergleich. Pharm. Ztg. 1996; 37: 33—42.